Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM Jr, Kraut EH, Hicks WJ, Chan KK, Chen CS, Farag SS, Grever MR, Byrd JC, Phelps MA. Hofmeister CC, et al. Among authors: farag ss. J Clin Oncol. 2011 Sep 1;29(25):3427-34. doi: 10.1200/JCO.2010.32.4962. Epub 2011 Aug 8. J Clin Oncol. 2011. PMID: 21825263 Free PMC article. Clinical Trial.
A phase I trial of flavopiridol in relapsed multiple myeloma.
Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC. Hofmeister CC, et al. Cancer Chemother Pharmacol. 2014 Feb;73(2):249-57. doi: 10.1007/s00280-013-2347-y. Epub 2013 Nov 16. Cancer Chemother Pharmacol. 2014. PMID: 24241210 Free PMC article. Clinical Trial.
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS. Benson DM Jr, et al. Among authors: farag ss. Blood. 2011 Dec 8;118(24):6387-91. doi: 10.1182/blood-2011-06-360255. Epub 2011 Oct 26. Blood. 2011. PMID: 22031859 Free PMC article.
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.
Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA. Poi MJ, et al. Among authors: farag ss. Clin Pharmacokinet. 2013 Aug;52(8):705-12. doi: 10.1007/s40262-013-0064-7. Clin Pharmacokinet. 2013. PMID: 23588536 Free PMC article. Clinical Trial.
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA. Blum W, et al. Among authors: farag ss. Biol Blood Marrow Transplant. 2006 Jan;12(1):61-7. doi: 10.1016/j.bbmt.2005.06.004. Biol Blood Marrow Transplant. 2006. PMID: 16399569 Free article.
95 results